| scholarly article | Q13442814 |
| P2093 | author name string | Wu W | |
| Russell RG | |||
| Tang R | |||
| Phipps RJ | |||
| Ebetino FH | |||
| Nancollas GH | |||
| Gulde S | |||
| Henneman Z | |||
| Mangood A | |||
| P433 | issue | 5 | |
| P304 | page(s) | 617-627 | |
| P577 | publication date | 2005-07-20 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite | |
| P478 | volume | 38 |
| Q36746390 | 'Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents |
| Q58147539 | (⁹⁹m)Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging |
| Q41986134 | A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone |
| Q36862150 | A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus |
| Q39575498 | A multimodal magnetic resonance imaging nanoplatform for cancer theranostics. |
| Q28247578 | A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro |
| Q33916132 | A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. |
| Q33921570 | A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years |
| Q57348746 | Ab initio investigation of the adsorption of zoledronic acid molecule on hydroxyapatite (001) surface: an atomistic insight of bone protection |
| Q87139853 | Actions of osteoporosis treatments on bone histomorphometric remodeling: a two-fold principal component analysis |
| Q34583705 | Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis |
| Q46898891 | Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules. |
| Q39817280 | Affinity of hydroxyapatite (001) and (010) surfaces to formic and alendronic acids: a quantum-mechanical and infrared study. |
| Q38643354 | Alendronate Functionalized Mesoporous Bioactive Glass Nanospheres. |
| Q38848318 | Alendronate-Eluting Biphasic Calcium Phosphate (BCP) Scaffolds Stimulate Osteogenic Differentiation |
| Q43139881 | An in vitro assay to measure targeted drug delivery to bone mineral |
| Q37051881 | An in vitro assessment of fibroblast and osteoblast response to alendronate-modified titanium and the potential for decreasing fibrous encapsulation. |
| Q59126038 | Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair |
| Q51194245 | Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. |
| Q39422812 | Anti-osteoporotic drug release from ordered mesoporous bioceramics: experiments and modeling |
| Q37794160 | Anticancer Properties of Zoledronic Acid |
| Q28071432 | Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature |
| Q38139294 | Atypical femoral fractures: a review of the literature |
| Q36633388 | Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality |
| Q53793096 | Bifunctional bisphosphonate complexes for the diagnosis and therapy of bone metastases. |
| Q92287293 | Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice |
| Q63991069 | Biomaterial Thin Films by Soft Pulsed Laser Technologies for Biomedical Applications |
| Q34182079 | Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment |
| Q45997666 | Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits. |
| Q37345838 | Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro |
| Q27004682 | Bisphosphonate drug holiday: choosing appropriate candidates |
| Q26830702 | Bisphosphonate therapy in pediatric patients |
| Q33665130 | Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. |
| Q46924536 | Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma |
| Q38104993 | Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. |
| Q33683219 | Bisphosphonates and bone quality |
| Q36443681 | Bisphosphonates for the treatment of osteoporosis: insights for clinicians |
| Q36897441 | Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice |
| Q37918967 | Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. |
| Q51873934 | Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. |
| Q41810819 | Bisphosphonates: An update |
| Q46292054 | Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. |
| Q59207343 | Bone mineral density measurements performed by cone-beam computed tomography in the bisphosphonate-related osteonecrosis-affected jaw |
| Q38066387 | Bone mineralization: from tissue to crystal in normal and pathological contexts |
| Q46284190 | Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy |
| Q33742858 | Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds |
| Q38364893 | Bone's Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment. |
| Q39356298 | Bone-seeking agents for the treatment of bone disorders |
| Q47557023 | CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws. |
| Q48225915 | Calcium Phosphates as Delivery Systems for Bisphosphonates. |
| Q34836666 | Calcium orthophosphates: crystallization and dissolution |
| Q84602527 | Can clodronate be effective in the treatment of disabling hydroxyapatite crystal-deposition disease? A report of two cases |
| Q35156035 | Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs |
| Q40160557 | Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting |
| Q35954529 | Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate |
| Q36311593 | Clinical role of bisphosphonate therapy |
| Q80344789 | Clodronic acid in the treatment of postmenopausal osteoporosis |
| Q85275415 | Combination therapy with risedronate and teriparatide in male osteoporosis |
| Q54205972 | Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis. |
| Q43797851 | Comparative physicochemical properties and cytotoxicity of polyphosphoester ionomers with bisphosphonates. |
| Q53064404 | Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. |
| Q35215353 | Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. |
| Q90394696 | Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study |
| Q37438653 | Complexation of bisphosphonates with ytterbium(III): application of phosphate and ATP detection assay based on Yb(3+)-pyrocatechol violet |
| Q35661168 | Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions |
| Q38381733 | Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial |
| Q44106490 | Crystalline calcium alendronate obtained by octacalcium phosphate digestion: a new chance for local treatment of bone loss diseases? |
| Q64245176 | Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management |
| Q37358122 | Current options for the treatment of Paget's disease of the bone. |
| Q30978614 | Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial |
| Q87340543 | Denosumab versus zoledronic acid in patients previously treated with zoledronic acid |
| Q57290351 | Density functional theory studies on a non-covalent interaction system: hydrogen-bonded dimers of zoledronate |
| Q48069145 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday |
| Q34042003 | Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis |
| Q53033362 | Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline. |
| Q36742845 | Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial |
| Q33557256 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? |
| Q80799437 | Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women? |
| Q37639315 | Drug delivery from ordered mesoporous matrices. |
| Q36576992 | Drug insight: Bisphosphonates for postmenopausal osteoporosis |
| Q30443800 | Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men. |
| Q64912464 | Dynamic Analyses of the Short-Term Effects of Different Bisphosphonates Using Intravital Two-Photon Microscopy. |
| Q33587793 | Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate |
| Q35127576 | Early tissue responses to zoledronate, locally delivered by bone screw, into a compromised cancellous bone site: a pilot study |
| Q46063122 | Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys |
| Q33841863 | Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate |
| Q39037530 | Effect of bisphosphonates on root resorption after tooth replantation - a systematic review |
| Q35767240 | Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model |
| Q36750128 | Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report |
| Q41091281 | Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study |
| Q51777430 | Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. |
| Q50491376 | Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients. |
| Q35230210 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study |
| Q63301892 | Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients |
| Q46760074 | Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study |
| Q51764274 | Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. |
| Q46293478 | Effects of etidronate on calcification of scales and ribs in the goldfish, Carassius auratus |
| Q39203039 | Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial |
| Q43689965 | Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties |
| Q34658660 | Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |
| Q33886852 | Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. |
| Q33965657 | Efficacy of ibandronate: a long term confirmation. |
| Q88019743 | Efficacy of zoledronic acid treatment in Paget disease of bone |
| Q35637157 | Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone |
| Q37145394 | Etidronate: what is its place in treatment of primary osteoporosis and other demineralizing diseases today? |
| Q39587433 | Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. |
| Q35156294 | Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo |
| Q42828847 | Fourier transform infrared imaging as a tool to chemically and spatially characterize matrix-mineral deposition in osteoblasts |
| Q50906434 | High-scale yield of nano hydroxyapatite through combination of mechanical activation and chemical dispersion. |
| Q92155512 | Highly Porous Amorphous Calcium Phosphate for Drug Delivery and Bio-Medical Applications |
| Q43172181 | Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. |
| Q51274540 | Hollow hydroxyapatite microsphere: a promising carrier for bone tissue engineering. |
| Q59806479 | Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment |
| Q57284392 | Hydroxyapatite with Permanent Electrical Polarization: Preparation, Characterization, and Response against Inorganic Adsorbates |
| Q46295408 | Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function |
| Q38750001 | Ibandronate: A Review in Japanese Patients with Osteoporosis |
| Q33933594 | Improved small molecule drug release from in situ forming poly(lactic-co-glycolic acid) scaffolds incorporating poly(β-amino ester) and hydroxyapatite microparticles |
| Q51653497 | In vitro and in vivo investigation of bisphosphonate-loaded hydroxyapatite particles for peri-implant bone augmentation. |
| Q64973324 | In vivo study and thermodynamic investigation of two lanthanum complexes, La(dpp)3 and La(XT), for the treatment of bone resorption disorders. |
| Q46292642 | In-vivo near-infrared optical imaging of growing osteosarcoma cell lesions xenografted in mice: dual-channel quantitative evaluation of volume and mineralization |
| Q34553500 | Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study |
| Q46291900 | Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. |
| Q89017404 | Influence of pH on osteoclasts treated with zoledronate and alendronate |
| Q53162076 | Influence of treadmill training on bone structure under osteometabolic alteration in rats subjected to high-fat diet. |
| Q35078785 | Infrared assessment of bone quality: a review |
| Q46987405 | Insights into the bisphosphonate holiday: a preliminary FTIRI study |
| Q48262033 | Interactions between Clinically Used Bisphosphonates and Bone Mineral: from Coordination Chemistry to Biomedical Applications and Beyond. |
| Q38766431 | Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. |
| Q24198280 | Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy |
| Q51487384 | Intravenous ibandronate acutely reduces bone hyperresorption in chronic critical illness. |
| Q37330296 | Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins |
| Q80167255 | Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease? |
| Q92005714 | Lactobacillus rhamnosus GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice via gut-microbiota-dependent anti-inflammation |
| Q35637145 | Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface. |
| Q42362884 | Local Administration of Bisphosphonate-soaked Hydroxyapatite for the Treatment of Osteonecrosis of the Femoral Head in Rabbit |
| Q48097165 | Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone |
| Q48212868 | Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone |
| Q34758140 | Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis |
| Q34018048 | Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis |
| Q51150701 | Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases. |
| Q37337113 | Management of osteoporosis in the aging male: focus on zoledronic acid |
| Q26782621 | Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research |
| Q37396476 | Mandibular necrosis in beagle dogs treated with bisphosphonates. |
| Q93135936 | Material properties and osteoporosis |
| Q34009569 | Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. |
| Q37397060 | Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience. |
| Q46991237 | Metabolic bone diseases |
| Q55077666 | Minodronate for the treatment of osteoporosis. |
| Q53743085 | Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors. |
| Q41855681 | Modification of Hydroxyapatite with Ion-Selective Complexants: 1-Hydroxyethane-1,1-diphosphonic Acid |
| Q34150056 | Molecular mechanisms of crystallization impacting calcium phosphate cements |
| Q91671758 | Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate |
| Q39444728 | Nanocrystalline carbonate-apatites: role of Ca/P ratio on the upload and release of anticancer platinum bisphosphonates |
| Q34073248 | Natural-abundance 43Ca solid-state NMR spectroscopy of bone. |
| Q35003623 | Neridronic acid for the treatment of bone metabolic diseases. |
| Q38962310 | Nitrogen-containing bisphosphonates modulate the antigenic profile and inhibit the maturation and biomineralization potential of osteoblast-like cells. |
| Q36703994 | OSTEOPOROSIS DIAGNOSIS AND TREATMENT. |
| Q34272000 | Once-monthly risedronate for postmenopausal osteoporosis |
| Q24657667 | Once-yearly zoledronic acid in hip fracture prevention |
| Q37192926 | Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women |
| Q36739172 | Open issues in anorexia nervosa: prevention and therapy of bone loss |
| Q57147876 | Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy |
| Q51196095 | Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. |
| Q42094867 | Osteonecrosis of maxilla secondary to bisphosphonate therapy: a case report |
| Q36939499 | Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis |
| Q57417202 | Osteoporosis |
| Q38002942 | Osteoporosis and osteopenia: implications for periodontal and implant therapy |
| Q38104738 | Osteoporosis treatment: why ibandronic acid? |
| Q37571428 | Paget disease: when to treat and when not to treat |
| Q39183207 | Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy |
| Q37170651 | Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases |
| Q34299982 | Peri-implant and systemic effects of high-/low-affinity bisphosphonate-hydroxyapatite composite coatings in a rabbit model with peri-implant high bone turnover |
| Q37430269 | Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders |
| Q37984490 | Pharmacotherapy of Paget's disease of bone. |
| Q37892992 | Physiology of the aging bone and mechanisms of action of bisphosphonates |
| Q33893639 | Polycaprolactone-coated 3D printed tricalcium phosphate scaffolds for bone tissue engineering: in vitro alendronate release behavior and local delivery effect on in vivo osteogenesis |
| Q26771713 | Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea |
| Q26864207 | Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective |
| Q45189900 | Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system |
| Q43039149 | Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. |
| Q42782576 | Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry |
| Q48136359 | Quercetin and alendronate multi-functionalized materials as tools to hinder oxidative stress damage |
| Q37197298 | Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats |
| Q53198094 | Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. |
| Q48510488 | Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function |
| Q46570247 | Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women |
| Q36984235 | Renal safety of intravenous bisphosphonates in the treatment of osteoporosis |
| Q37264078 | RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction |
| Q35059092 | Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice |
| Q36952170 | Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday |
| Q34984177 | Role of zoledronic acid in the prevention and treatment of osteoporosis |
| Q35026446 | Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management |
| Q47912290 | Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis |
| Q46268511 | Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. |
| Q38691919 | Simulations of inorganic-bioorganic interfaces to discover new materials: insights, comparisons to experiment, challenges, and opportunities |
| Q89280856 | Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease |
| Q33881531 | Smart, programmable and responsive injectable hydrogels for controlled release of cargo osteoporosis drugs. |
| Q43183249 | Specificity of the zinc(II), magnesium(II) and calcium(II) complexation by (pyridin-2-yl)aminomethane-1,1-diphosphonic acids and related 1,3-(thiazol-2-yl) and 1,3-(benzothiazol-2-yl) derivatives. |
| Q39550317 | Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters. |
| Q42408282 | Superparamagnetic bifunctional bisphosphonates nanoparticles: a potential MRI contrast agent for osteoporosis therapy and diagnostic. |
| Q42881598 | Surface immobilized zoledronate improves screw fixation in rat bone: a new method for the coating of metal implants |
| Q41115341 | Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion |
| Q64251161 | Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication) |
| Q50643735 | Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(ε-caprolactone)/hydroxyapatite microspheres. |
| Q40494818 | Synthesis, solution, and structural characterization of tetrahydrofuranyl-2,2-bisphosphonic acid disodium salt. |
| Q35682511 | Systemic immunity shapes the oral microbiome and susceptibility to bisphosphonate-associated osteonecrosis of the jaw. |
| Q37476433 | Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model |
| Q39830389 | Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis |
| Q37068993 | Teriparatide in the management of osteoporosis |
| Q35012189 | The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue. |
| Q43466832 | The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids. |
| Q38247428 | The critical role of bisphosphonates to target bone cancer metastasis: an overview. |
| Q48001390 | The effect of bisphosphonate acidity on the activity of a thymidylyltransferase |
| Q42852080 | The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts |
| Q42478623 | The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. |
| Q37832692 | The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. |
| Q64928365 | The effects of bisphosphonates on osteoporotic patients after lumbar fusion: a meta-analysis. |
| Q39556401 | The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation |
| Q35842418 | The effects of zoledronate on the survival and function of human osteoblast-like cells |
| Q37296051 | The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink |
| Q36795687 | Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis |
| Q83033686 | To stop or not to stop, that is the question |
| Q38934877 | Tracking calcification in tissue-engineered bone using synchrotron micro-FTIR and SEM. |
| Q37822757 | Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy. |
| Q41995909 | Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis |
| Q36056932 | Treatment of glucocorticoid-induced osteoporsis |
| Q37346608 | Treatment of osteoporotic intertrochanteric fractures by zoledronic acid injection combined with proximal femoral nail anti-rotation |
| Q98830514 | Updated approach for the management of osteoporosis in Turkey: a consensus report |
| Q79610649 | Weekly alendronate versus risedronate for postmenopausal osteoporosis--is there a difference? |
| Q43268923 | Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome |
| Q36645076 | Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem Cells without Change in Hypomethylation Status of OSTERIX Promoter |
| Q39013796 | Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis |
| Q36059331 | Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis |
| Q37101547 | Zoledronic acid : a review of its use in the management of bone metastases of malignancy |
| Q36979355 | Zoledronic acid for treatment of Paget's disease of bone |
| Q47139370 | Zoledronic acid in pediatric metabolic bone disorders |
| Q37354133 | Zoledronic acid: a review of its use in breast cancer |
| Q36770342 | Zoledronic acid: a review of its use in the treatment of Paget's disease of bone |
| Q37306784 | Zoledronic acid: a review of its use in the treatment of osteoporosis |
| Q35394505 | pH-activated nanoparticles for controlled topical delivery of farnesol to disrupt oral biofilm virulence |
| Q34317633 | pH-responsive NIR enhanced drug release from gold nanocages possesses high potency against cancer cells |
Search more.